GO:0046761 viral budding from plasma membrane: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046761 (viral budding from plasma membrane) describes the process by which enveloped virions assemble at and bud from the host cell plasma membrane, initiating with membrane curvature around the assembling particle [2, 7, 8].
• The process is driven by viral structural proteins (Gag, M, HA/NA) that recruit host ESCRT machinery and lipid microdomains to complete membrane scission [2, 6, 7].
• Influenza A virus assembly and budding is a paradigm for this GO term, with recent cryo-electron tomography revealing in situ budding intermediates.
• Host factors such as Rab27a regulate transport of viral membrane proteins to the plasma membrane, directly impacting budding efficiency.
• Dysregulation of membrane budding is linked to autoimmune kidney disease through autoantibody-triggered podocyte membrane budding, highlighting broader pathophysiological relevance.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect the roles of viral and host genes in plasma membrane budding [2, 6].
Description
Viral budding from the plasma membrane (GO:0046761) is a biological process that defines the final step in the replication cycle of many enveloped viruses, including influenza A virus, HIV-1, and other retroviruses [2, 7, 8]. This process begins with the formation of a curvature in the host plasma membrane, around which the virion particle assembles, ultimately leading to the release of a membrane-enveloped virion [2, 8]. Understanding this process is critical for virology, antiviral drug development, and cell biology, as it represents a convergence of viral and host machinery [6, 7]. The term is distinct from other budding processes, such as nuclear egress of herpesviruses, which occurs at the nuclear membrane rather than the plasma membrane. Recent advances in imaging and molecular biology have provided unprecedented detail on the spatiotemporal dynamics of plasma membrane budding, revealing how viral proteins hijack host lipid and protein trafficking pathways [4, 5]. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0046761, covering its definition, mechanism, key genes, disease links, and experimental models.
viral budding from plasma membrane At A Glance
| GO ID | GO:0046761 |
|---|---|
| GO term | viral budding from plasma membrane |
| Ontology | biological_process |
| Synonym | plasma membrane viral budding; virus budding from plasma membrane; viral budding from plasma membrane during viral capsid envelopment |
| Major function | Release of enveloped virions from the host cell plasma membrane |
| Definition | A viral budding that starts with formation of a curvature in the host plasma membrane around which the virion particle assembles. |
| Related process | Viral membrane scission; ESCRT-mediated budding |
| Key viral proteins | Gag (retroviruses), M1/M2 (influenza), HA/NA (influenza) |
| Key host factors | ESCRT complexes, Rab27a, lipid rafts |
What Is GO:0046761?
According to the Gene Ontology, GO:0046761 (viral budding from plasma membrane) is defined as a viral budding that starts with formation of a curvature in the host plasma membrane around which the virion particle assembles. In simpler terms, it is the process by which a virus pushes outward from the host cell surface, wrapping itself in a piece of the plasma membrane to form its envelope, and then pinches off to become a free infectious particle [2, 8].
Why Is viral budding from plasma membrane Important in Cell Biology?
GO:0046761 is a central step in the life cycle of enveloped viruses and represents a key target for antiviral therapies and vaccine development [2, 7]. Because budding from the plasma membrane is the final step before virion release, inhibiting this process can block viral spread [6, 8]. Moreover, the mechanisms of membrane curvature and scission are shared with cellular processes such as multivesicular body formation and cytokinesis, making this term relevant to broader cell biology [2, 7]. Recent studies have also linked dysregulated membrane budding to autoimmune diseases, underscoring its importance beyond virology.
• Essential for the release of enveloped viruses such as influenza A, HIV-1, and Ebola [2, 7].
• Represents a prime target for antiviral drugs that block membrane scission or viral protein trafficking.
• Influenza A virus assembly and budding is a model system for studying plasma membrane budding.
• Host factors like Rab27a regulate viral protein transport to the plasma membrane, affecting budding efficiency.
• Dysregulation of membrane budding is implicated in autoimmune kidney disease via podocyte membrane budding.
• Understanding budding mechanisms aids in the design of pseudotyped viral vectors for gene therapy.
• Lipid-protein interactions at the plasma membrane are critical for budding and are studied using advanced imaging.
• The process is distinct from nuclear egress of herpesviruses, highlighting compartment-specific budding.
• CRISPR screens have identified host dependency factors for viral budding, offering new therapeutic targets.
• Budding intermediates can be visualized by cryo-electron tomography, providing structural insights.
What Happens During viral budding from plasma membrane?
Initiation and Membrane Curvature
In simple terms: The virus starts to push out from the cell surface, bending the membrane outward.
The process begins when viral structural proteins, such as the Gag polyprotein of retroviruses or the M1 protein of influenza A virus, accumulate at the inner leaflet of the plasma membrane [2, 7]. These proteins interact with specific lipid microdomains, including cholesterol-rich rafts, and induce a local curvature in the membrane. This curvature is the first morphological sign of budding and is driven by protein-protein and protein-lipid interactions that create a platform for virion assembly [2, 8].
Virion Assembly and Budding
In simple terms: The viral components gather at the curved membrane and form a new virus particle.
Following curvature initiation, viral glycoproteins embedded in the plasma membrane, such as influenza hemagglutinin (HA) and neuraminidase (NA), are incorporated into the budding site [4, 5]. The viral core, composed of capsid proteins and the viral genome, is recruited to the budding neck. In retroviruses, Gag drives the assembly of the immature virion, while in influenza, the ribonucleoprotein complexes are packaged [2, 7]. Recent in situ cryo-electron tomography has visualized these assembly intermediates in influenza A virus-infected cells, revealing the ordered recruitment of viral components.
Membrane Scission
In simple terms: The virus pinches off from the cell membrane, becoming free.
The final step of budding is membrane scission, which releases the virion. For many enveloped viruses, this requires the host ESCRT (Endosomal Sorting Complex Required for Transport) machinery, which is recruited to the budding neck by viral late-domain motifs [2, 7]. ESCRT-III components, such as CHMP4, mediate the constriction and scission of the membrane neck. Some viruses, like influenza A, can bud in an ESCRT-independent manner, utilizing the viral M2 protein and lipid composition to facilitate scission [6, 8]. The scission event is tightly regulated and is a target for antiviral intervention.
Host Factors and Regulation
In simple terms: The cell's own proteins help or hinder the virus during budding.
Host proteins play critical roles in viral budding from the plasma membrane. Rab27a regulates the transport of influenza virus membrane proteins (HA and NA) to the plasma membrane, and its depletion reduces budding efficiency. Lipid composition, particularly the presence of cholesterol and sphingolipids, influences membrane fluidity and curvature. Additionally, the ESCRT pathway is a major host factor for retroviral budding, and its components are often targeted by viral proteins [2, 7]. Post-translational modifications of viral proteins, such as ubiquitination, also regulate their trafficking and budding activity.
Key Genes Involved in GO:0046761 viral budding from plasma membrane
The following genes and proteins are central to the process of viral budding from the plasma membrane, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Gag (retroviral) | Drives assembly and budding of retroviruses at the plasma membrane | Model for ESCRT-dependent budding; target for antiviral drugs [2, 7] |
| M1 (influenza A) | Matrix protein that links viral RNPs to the membrane and induces curvature | Key for influenza assembly; studied by cryo-ET |
| M2 (influenza A) | Ion channel that facilitates membrane scission in influenza budding | ESCRT-independent scission mechanism |
| HA (influenza A) | Viral glycoprotein incorporated into budding virions | Transport regulated by Rab27a; target for neutralizing antibodies |
| NA (influenza A) | Viral glycoprotein that aids in release by cleaving sialic acid | Budding efficiency and drug target (oseltamivir) |
| Rab27a | Host GTPase that regulates transport of viral membrane proteins to plasma membrane | Knockout reduces influenza budding; potential host-directed target |
| ESCRT-III (CHMP4B) | Host machinery for membrane scission | Essential for retroviral budding; target for broad-spectrum antivirals |
| TSG101 | ESCRT-I component recruited by viral late domains | Required for HIV-1 budding; studied by knockout [2, 7] |
| ALIX | ESCRT-associated protein that binds viral late domains | Facilitates budding of some retroviruses |
| VPS4 | AAA-ATPase that recycles ESCRT components | Dominant-negative mutants block budding |
| CD63 | Tetraspanin enriched in exosomes and viral budding sites | Marker for multivesicular body and viral budding |
| NPC1 | Cholesterol transporter involved in Ebola budding | Host factor for filovirus budding |
| Actin | Cytoskeletal element that facilitates budding site organization | Inhibitors reduce budding efficiency |
| Clathrin | Endocytic protein that can be co-opted for budding | Role in some enveloped virus budding |
| Caveolin | Membrane protein associated with lipid rafts | Potential role in budding of certain viruses |
| Interferon-induced transmembrane proteins (IFITMs) | Restrict viral entry and budding | Knockout increases budding; antiviral mechanism |
| Tetherin (BST2) | Host restriction factor that inhibits virion release | Knockout enhances budding; viral antagonists (Vpu) counteract |
How Is viral budding from plasma membrane Regulated?
The process of viral budding from the plasma membrane is regulated at multiple levels. Host cell signaling pathways, including those involving Rab GTPases, control the trafficking of viral proteins to the plasma membrane. The ESCRT pathway is tightly regulated by ATPases such as VPS4, which recycle ESCRT components for multiple rounds of budding. Lipid metabolism and membrane composition also modulate budding efficiency, as cholesterol-rich microdomains are preferred sites for assembly. Additionally, interferon-induced restriction factors like tetherin can inhibit virion release, and viruses have evolved antagonists to counteract them. Post-translational modifications, including ubiquitination and phosphorylation of viral proteins, further regulate budding.
viral budding from plasma membrane and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Gag (HIV-1) | AIDS | Knockout of host ESCRT genes in T cells; overexpression of Gag [2, 7] |
| M2 (influenza A) | Influenza | Point mutation to abolish ion channel activity; knockout in viral genome |
| Rab27a | Influenza susceptibility | CRISPR knockout in lung epithelial cells; overexpression |
| Tetherin (BST2) | Viral restriction | Knockout to enhance budding; knock-in of viral antagonist |
| NPC1 | Ebola virus disease | Knockout in macrophages; small molecule inhibitors |
Viral Infections and Antiviral Targets
GO:0046761 is directly implicated in the pathogenesis of enveloped virus infections, including influenza, HIV/AIDS, and Ebola. Inhibiting budding from the plasma membrane blocks viral spread and is a validated antiviral strategy [2, 6, 7]. For example, oseltamivir targets influenza neuraminidase, which is required for efficient release of budding virions. Host factors like Rab27a and ESCRT components are also being explored as host-directed antiviral targets [2, 4].
Autoimmune Kidney Disease
Recent evidence links autoantibody-triggered podocyte membrane budding to autoimmune kidney disease, suggesting that dysregulated membrane budding processes can contribute to pathology beyond viral infections. This highlights the broader relevance of membrane budding mechanisms in human disease.
Cancer and Oncolytic Viruses
Oncolytic viruses that bud from the plasma membrane are being developed as cancer therapeutics. Understanding the budding process can enhance the efficacy and safety of these viruses by optimizing their replication and spread within tumors. Additionally, some viruses that bud from the plasma membrane are associated with oncogenesis, such as human T-cell leukemia virus type 1 (HTLV-1).
From viral budding from plasma membrane-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate influenza budding? | CRISPR knockout of host gene in A549 cells followed by viral titer |
| What is the role of a viral late domain in ESCRT recruitment? | Point mutation of late domain in viral genome; budding assay |
| Can a host factor be tagged for live imaging? | Knock-in of fluorescent tag (e.g., GFP) at endogenous locus |
| Does overexpression of a restriction factor block budding? | Overexpression of tetherin or IFITM in permissive cells |
| What is the effect of a lipid-modifying enzyme on budding? | Knockout of cholesterol synthesis genes; lipidomics |
| Can CRISPR screen identify novel budding factors? | Genome-wide knockout library in cells infected with reporter virus |
How to Study the viral budding from plasma membrane Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-electron tomography | 3D ultrastructure of budding intermediates | Visualizing influenza A assembly |
| Live-cell fluorescence microscopy | Real-time dynamics of viral and host proteins | Tracking Gag recruitment to plasma membrane |
| Plaque assay | Infectious virion release | Quantifying budding efficiency |
| Western blot for viral proteins | Protein expression and incorporation into virions | Assessing Gag processing and release |
| CRISPR knockout screen | Host genes required for budding | Identifying ESCRT and Rab factors |
| Lipidomics | Membrane lipid composition at budding sites | Role of cholesterol in budding |
| Proteomics | Protein-protein interactions at budding sites | Identifying novel host factors |
| RNA-seq | Transcriptional changes during infection | Host response to budding |
Cryo-Electron Tomography
In situ cryo-electron tomography has been used to visualize influenza A virus assembly and budding intermediates at near-atomic resolution, revealing the ultrastructure of budding sites and the arrangement of viral components. This method is powerful for studying the spatial organization of budding without chemical fixation artifacts.
Fluorescence Microscopy and Live Imaging
Live-cell fluorescence microscopy with tagged viral proteins (e.g., Gag-GFP) allows real-time tracking of budding events and the recruitment of host factors [2, 4]. Total internal reflection fluorescence (TIRF) microscopy is particularly useful for observing plasma membrane budding dynamics.
Viral Titer and Budding Assays
Classical virological assays, such as plaque assays and focus-forming assays, quantify infectious virion release. Budding efficiency can be measured by comparing cell-associated versus released viral particles using Western blot or qRT-PCR [2, 7].
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout screens have identified host dependency factors for viral budding, such as ESCRT components and Rab GTPases. These screens are instrumental in discovering new therapeutic targets and understanding host-virus interactions.
How CRISPR Can Be Used to Study GO:0046761 viral budding from plasma membrane
Knockout
CRISPR knockout of host genes such as Rab27a or ESCRT components has been used to demonstrate their essential roles in viral budding from the plasma membrane [2, 4]. For example, Rab27a knockout reduces influenza virus budding by impairing transport of HA and NA to the plasma membrane. Knockout of ESCRT-III subunits blocks retroviral budding.
Point Mutation
Point mutations can be introduced into viral genomes to dissect the function of specific motifs, such as the PTAP late domain in Gag that recruits TSG101. CRISPR-based base editing allows precise introduction of such mutations to study their effect on budding without altering other viral functions.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) at endogenous loci enables live-cell imaging of host factors during budding. Knock-in of viral genes with epitope tags facilitates purification and proteomic analysis of budding complexes.
Overexpression
Overexpression of restriction factors like tetherin or IFITM proteins inhibits viral budding and can be used to study host defense mechanisms. Conversely, overexpression of viral proteins such as Gag or M1 can drive budding in the absence of infection, allowing dissection of minimal requirements.
How EDITGENE Supports viral budding from plasma membrane Research
Researchers studying viral budding from plasma membrane-related genes often need to determine whether a candidate gene is causally involved in the budding process or is merely a bystander. CRISPR-based models provide the gold standard for establishing causality by enabling precise genetic perturbations in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for viral budding from plasma membrane research.
Frequently Asked Questions About viral budding from plasma membrane
What is viral budding from plasma membrane (GO:0046761)?
It is the process by which enveloped viruses assemble at and bud from the host cell plasma membrane, forming a curvature around the virion and releasing it [2, 8].
What genes are involved in viral budding from plasma membrane?
Key genes include viral Gag, M1, HA, and NA, as well as host genes like Rab27a, ESCRT components (TSG101, CHMP4B), and tetherin [2, 4, 7].
How does influenza A virus bud from the plasma membrane?
Influenza A virus uses its M1 protein to induce membrane curvature and M2 for scission, while HA and NA are incorporated into the budding virion [5, 6].
What is the role of ESCRT in viral budding?
The ESCRT machinery mediates membrane scission for many enveloped viruses, including HIV-1, by being recruited to the budding neck via viral late domains [2, 7].
Can CRISPR be used to study viral budding?
Yes, CRISPR knockout, knock-in, and overexpression models are widely used to dissect the roles of host and viral genes in budding [2, 4].
What diseases are associated with viral budding from plasma membrane?
Infections by enveloped viruses such as influenza, HIV, and Ebola, as well as autoimmune kidney disease linked to podocyte membrane budding [1, 2, 6].
How is viral budding from plasma membrane visualized?
Advanced imaging techniques like cryo-electron tomography and live-cell fluorescence microscopy allow visualization of budding intermediates.
What is the difference between viral budding from plasma membrane and other budding processes?
Plasma membrane budding occurs at the cell surface, whereas other processes like herpesvirus nuclear egress occur at the nuclear membrane.
What host factors regulate viral budding from plasma membrane?
Rab27a regulates transport of viral proteins, ESCRT mediates scission, and lipid rafts provide a platform for assembly [2, 4, 6].
How can I create a knockout cell line for a gene involved in viral budding?
EDITGENE offers custom CRISPR knockout services for host genes such as Rab27a and ESCRT components, with full validation [2, 4].
Conclusion
GO:0046761 (viral budding from plasma membrane) is a fundamental biological process that enables the release of enveloped viruses and is a key target for antiviral therapies. Understanding its molecular mechanisms, host dependencies, and regulation is essential for developing interventions against influenza, HIV, and other viral pathogens. Recent advances in imaging and CRISPR technologies continue to unravel the complexities of this process, offering new opportunities for therapeutic discovery [2, 5, 6].
References
- 1. Lahme K et al.. 2026. Autoantibody-triggered podocyte membrane budding drives autoimmune kidney disease.. Cell 189(1):123-142.e30 PMID: 41349547
- 2. Rossman JS et al.. 2013. Viral membrane scission.. Annu Rev Cell Dev Biol 29:551-69 PMID: 24099087
- 3. Roller RJ et al.. 2017. Herpesvirus Nuclear Egress.. Adv Anat Embryol Cell Biol 223:143-169 PMID: 28528443
- 4. Chen T et al.. 2025. Rab27a regulates the transport of influenza virus membrane proteins to the plasma membrane.. Nat Commun 16(1):6271 PMID: 40623997
- 5. Wachsmuth-Melm M et al.. 2025. Visualizing influenza A virus assembly by in situ cryo-electron tomography.. Nat Commun 16(1):9394 PMID: 41130956
- 6. Motsa BB et al.. 2021. Lipid-protein interactions in virus assembly and budding from the host cell plasma membrane.. Biochem Soc Trans 49(4):1633-1641 PMID: 34431495
- 7. Morita E et al.. 2004. Retrovirus budding.. Annu Rev Cell Dev Biol 20:395-425 PMID: 15473846
- 8. Cadd TL et al.. 1997. Budding of enveloped viruses from the plasma membrane.. Bioessays 19(11):993-1000 PMID: 9394621
